Why I think these 2 ASX growth shares are great buys today

These two ASX growth shares look like top buys. Here's why.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • Pro Medicus recently announced contracts worth $73 million, boosting earnings and driving over 30% growth in profit and dividends, despite a 20% share price decline since July.
  • Temple & Webster's revenue growth slowed to 18% YTD, but its long-term prospects remain positive with potential for increased online market penetration.
  • Both companies are set for future growth, leveraging strong market positions and operational efficiencies to enhance profit margins and market share.

ASX growth shares can generate some of the strongest returns over time, but there can be plenty of volatility along the way. I'm going to highlight two companies that have exciting futures and whose recent valuation declines have made them appear better value.

It's normal for fast-growing businesses to sometimes experience a bump. There have been numerous sell-offs, for example, of Amazon and Microsoft shares over the last 30 years. Those dips were opportunities.

I'm not expecting the following two businesses to do as well as the US tech giants, but the future looks positive for these stocks.

Sport trainer talking to little girl who is climbing wooden ladder in gym.

Image source: Getty Images

Pro Medicus Ltd (ASX: PME)

Pro Medicus is one of the most impressive ASX growth shares, in my view. It provides a full range of medical imaging software and services to hospitals, imaging centres, and healthcare groups in Australia and internationally.

The company is winning a lot of new contracts, which is driving its earnings higher at a rapid rate. In this month alone, it has announced multiple contracts worth a total of $73 million. Large clients are clearly loving what they're seeing with the offering.

This new revenue is extremely valuable to the business because it has an underlying operating profit (EBIT) margin of 74% (as of FY25). That means almost three-quarters of revenue is turning into EBIT, which is a very high proportion. This is helping drive the bottom line and dividends to higher levels at a growth rate of more than 30% (in FY25).

Its FY25 revenue rose 31.9% and it seems the company is set to deliver further strong growth for the foreseeable future.

The ASX growth share still has a high price-to-earnings (P/E) ratio, but it appears considerably cheaper after the Pro Medicus share price declined by 20% since July, as the chart below shows.

Temple & Webster Group Ltd (ASX: TPW)

This company sells homewares and furniture online. The ASX growth share took a hammering yesterday after delivering a trading update that didn't live up to expectations. I think this is a long-term buying opportunity.

Revenue between 1 July 2025 and 20 November 2025 grew by only 18% year over year, compared to the 28% growth achieved between 1 July and 11 August 2025. It's clear there has been a major slowdown since August.

However, the company has a long history of delivering strong growth, so I believe this is just a temporary hit for the ASX growth share rather than a permanent situation.

For starters, the overall Australian furniture and homewares market only recently reached 20% online penetration. In the US and UK markets, online penetration has climbed to 29% and 35%, respectively, suggesting a further increase in e-commerce adoption by shoppers.

With 18% revenue growth for the financial year to date, the company is still gaining market share, giving it more market power and economies of scale.

The business noted a number of other positives in its AGM update – it's starting to ship products to New Zealand, its home improvement revenue rose over 40% year over year, and the trade and commercial revenue increased 23% year over year.

I'm expecting the company's revenue to be significantly higher in five years, and the profit margins should climb thanks to operating leverage and specific efforts the ASX growth share is making to improve efficiencies, leverage AI, and enhance technology across the business.

Motley Fool contributor Tristan Harrison has positions in Pro Medicus and Temple & Webster Group. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Amazon, Microsoft, and Temple & Webster Group. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Pro Medicus and has recommended the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool Australia has recommended Amazon, Microsoft, Pro Medicus, and Temple & Webster Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Growth Shares

A couple are happy sitting on their yacht.
Growth Shares

What are the best Australian shares to buy now to try and make a million?

Looking to build wealth over the long-term? These shares could help.

Read more »

Purple tech growth chart.
Growth Shares

2 wonderful ASX All Ords stocks I'd buy today

These stocks could deliver great returns. Here’s why…

Read more »

Cheerful man in a orange shirt standing in front of an audience holding a tablet and using hand gestures to interact with the audience.
Growth Shares

3 amazing ASX growth shares that continue to stand out

Looking for growth options? Here are three to consider.

Read more »

Person pointing finger on on an increasing graph which represents a rising share price.
Growth Shares

2 ASX shares tipped to grow at least 50% in the next 12 months

These stocks could be some of the best ones to own today.

Read more »

Scared looking people on a rollercoaster ride representing volatility.
Growth Shares

What's driving the wild swings in Telix shares?

The ASX biotech stock offers high-growth potential, but it comes with volatility.

Read more »

An executive in a suit smooths his hair and laughs as he looks at his laptop feeling surprised and delighted.
Growth Shares

3 stellar ASX growth shares to buy now with 30% to 70% upside

Analysts have buy ratings and lofty price targets on these shares.

Read more »

Person using a calculator with four piles of coins, each getting higher, with trees on them.
Growth Shares

2 ASX shares that I rate as buys today for both growth and dividends!

These businesses have plenty going for them. I’m calling them buys…

Read more »

Two excited woman pointing out a bargain opportunity on a laptop.
Share Market News

NextDC shares rocket 27% higher: Buy, hold or sell?

Can NextDC shares keep climbing higher, or have they now peaked?

Read more »